Chen Chao, Zhang Wei, Zhou Daobin, Zhang Yan
Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences (CAMS), Beijing, China.
Front Oncol. 2021 Nov 8;11:757403. doi: 10.3389/fonc.2021.757403. eCollection 2021.
Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully treated with sintilimab and chidamide. The patient was a 71-year-old man with pulmonary mucosa-associated lymphoid tissue lymphoma. He did not receive any treatment until tDLBCL was confirmed 2 years later. The tDLBCL was primary refractory to R2-CHOP, R2-MTX, and Gemox regimens. However, the patient achieved sustained complete remission after the combination therapy of sintilimab and chidamide. To the best of our knowledge, this is the first report of sintilimab combined with chidamide for the treatment of R/R tDLBCL, which opens up new therapeutic possibilities for this new combination therapy in future prospective clinical trials.
复发/难治性（R/R）转化型弥漫性大B细胞淋巴瘤（tDLBCL）患者预后较差，生存率较低。此外，R/R tDLBCL尚未确立标准治疗方案。在此，我们报告了1例R/R tDLBCL患者，其接受信迪利单抗和西达本胺治疗成功。该患者为1名71岁男性，患有肺黏膜相关淋巴组织淋巴瘤。2年后确诊为tDLBCL之前，他未接受任何治疗。tDLBCL对R2-CHOP、R2-MTX和吉西他滨联合奥沙利铂方案原发难治。然而，该患者在接受信迪利单抗和西达本胺联合治疗后实现了持续完全缓解。据我们所知，这是信迪利单抗联合西达本胺治疗R/R tDLBCL的首例报告，为该新联合疗法在未来前瞻性临床试验中开辟了新的治疗可能性。
